LB Pharma’s Novel Antipsychotic LB-102 Shows Promise in Phase II Schizophrenia Trial

LB-102 is a once-daily oral benzamide antipsychotic being developed as a potential first-in-class treatment for schizophrenia in the US13.
The Phase II NOVA1 trial enrolled 359 adults with acute schizophrenia and met its primary endpoint, showing statistically significant reductions in PANSS total scores compared to placebo across all tested doses13.
The 50 mg dose showed a 5.0-point PANSS reduction (p=0.0009), 75 mg showed a 4.7-point reduction (p=0.0022), and 100 mg showed a 6.8-point reduction (p=0.0017) compared to placebo310.
LB-102 was generally safe and well-tolerated, with low incidence of extrapyramidal symptoms, minimal QT prolongation, and average weight gain of 2 kg13.
LB Pharma plans to advance LB-102 to Phase III trials, explore its potential in other psychiatric indications, and develop a long-acting injectable formulation13.
If approved, LB-102 could become the first benzamide antipsychotic available in the US, potentially offering a new treatment option for patients with schizophrenia13.

Sources:

1. https://www.drugtargetreview.com/news/155351/lb-pharma-positive-schizophrenia-trial/

3. https://www.biospace.com/press-releases/lb-pharmaceuticals-announces-positive-topline-results-from-phase-2-trial-of-lb-102-in-schizophrenia

10. https://www.hcplive.com/view/phase-2-lb-102-data-advancing-treatment-landscape-in-schizophrenia-with-john-kane-md